Combination of palbociclib and erlotinib exhibits synergistic antitumor effect in colorectal cancer
CSTR:
Author:
Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective:This stndy aims to evaluate the efficacy of palbociclib alone or in combination with the epidermal growth factor receptor inhibitor erlotinib in the treatment of colorectal cancer(CRC). Methods:Alamar bule method and clone formation assay were used to detect the effects of palbociclib alone or in combination with erlotinib on the proliferation of CRC cell lines. Cell cycle distribution was determined by DNA content. Cell senescence and reactive oxygen species (ROS) accumulation were detected by β-galactosidase and DCFH-DA staining. The expression levels of related proteins were analyzed by Western blot and their clinical efficacies were evaluated in CRC patient-derived xenograft models. Results:Palbociclib inhibits CRC cell proliferation,induce G1 cell arrest,cell senescence and intracellular ROS accumulation effectively. Combination of palbociclib and erlotinib exhibits synergistic effects on CRC,and erlotinib further enhances the multiple inhibitory effects and multi-signaling pathway inhibition of palbociclib on CRC. Synergistic inhibition was also shown in CRC patient-derived xenograft models. Conclusion:Palbociclib combined with erlotinib synergistically inhibits the growth activity of colorectal cancer in vitro and in vivo.

    Reference
    Related
    Cited by
Get Citation

周小晖,贡叶清,刘晓蓉,林 凡.帕博西尼和厄洛替尼联合治疗结直肠癌的协同作用及其机制[J].南京医科大学学报(自然科学版英文版),2021,(8):1121-1127.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:March 03,2021
  • Revised:
  • Adopted:
  • Online: August 30,2021
  • Published:
Article QR Code